SU2C-St. Baldrick Pediatric Team Finds New Target in Neuroblastoma - Stand Up To Cancer

News

SU2C-St. Baldrick Pediatric Team Finds New Target in Neuroblastoma

Scientists supported by the Stand Up To Cancer-St. Baldrick’s Foundation Pediatric Cancer Dream Team have identified a promising new target for possible treatment of neuroblastoma, the most common cancer in infants. “We have built a strong foundation for developing a completely new and hopefully much less toxic treatment for neuroblastoma,” said John M. Maris, MD, a pediatric oncologist at Children’s Hospital of Philadelphia (CHOP) who is leader of the Dream Team and supervised a study published in Cancer Cell, a prestigious scientific journal. Crystal Mackall, MD, associate director of the Stanford Cancer Institute and co-leader of the Dream Team, is also a co-author of the paper. Maris, Mackall,and colleagues identified a protein that occurs on the surface of the tumor cells and then developed a combination of an antibody that zeroes in on the protein and a chemotherapy drug that attacks the DNA in the tumors while sparing healthy tissue. 

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.